Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by Quantum BioPharma

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Announces Corporate Updates
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM GME QNTM
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Clarifies It Has Not Changed Its Name
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM MDCX QNTM
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
Tickers CSE:QNTM QNTM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.